Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report

Kahlenborn, Chris and Severs, Walter B. and Nawab, Khalid (2022) Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report. Frontiers in Drug Discovery, 2. ISSN 2674-0338

[thumbnail of pubmed-zip/versions/1/package-entries/fddsv-02-962988/fddsv-02-962988.pdf]

Text
pubmed-zip/versions/1/package-entries/fddsv-02-962988/fddsv-02-962988.pdf - Published Version
Download (5MB)

Official URL: https://doi.org/10.3389/fddsv.2022.962988

Abstract

Various literature cited suggests that bismuth may have usefulness against Covid-19 both in vitro and in vivo. During the course of caring for Covid-19 patients we administered bismuth subsalicylate to those who displayed diarrhea and/or gastric complaints. Using relatively conservative criteria, upon retrospective review, we noted marked improvement in oxygen requirements in most of the cases. This improvement was observed even when prior therapy with standard anti-Covid drugs had failed. Our overall impression is that these positive results support a detailed evaluation of bismuth as an adjunct treatment for the treatment of Covid-19.

Item Type:	Article
Subjects:	Science Repository > Medical Science
Depositing User:	Managing Editor
Date Deposited:	18 Jan 2023 10:28
Last Modified:	30 Dec 2023 13:15
URI:	http://research.manuscritpub.com/id/eprint/648

Actions (login required)

: View Item